SEPN to report oral PTH agonist Phase I data in Q1
SEPN is advancing an oral PTH receptor agonist for hypoparathyroidism, with full Phase I data expected in Q1 next year. The company is also expanding into Graves' disease, osteoporosis and mast cell diseases.